Cargando…
GP‐2250, a novel anticancer agent, inhibits the energy metabolism, activates AMP‐Kinase and impairs the NF‐kB pathway in pancreatic cancer cells
GP‐2250, a novel anticancer agent, severely limits the energy metabolism, as demonstrated by the inhibition of hexokinase 2 and glyceraldehyde‐3‐phosphate dehydrogenase and a decrease of ATP. Rescue experiments with supplementary pyruvate or oxaloacetate demonstrated that a TCA cycle deficit largely...
Autores principales: | Majchrzak‐Stiller, Britta, Buchholz, Marie, Peters, Ilka, Waschestjuk, Daniel, Strotmann, Johanna, Höhn, Philipp, Hahn, Stephan, Braumann, Chris, Uhl, Waldemar, Müller, Thomas, Möhler, Hanns |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339077/ https://www.ncbi.nlm.nih.gov/pubmed/37390227 http://dx.doi.org/10.1111/jcmm.17825 |
Ejemplares similares
-
Substance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma—A 3-D In Vitro Study
por: Baron, Claudia, et al.
Publicado: (2022) -
New Therapy Options for Neuroendocrine Carcinoma of the Pancreas—The Emergent Substance GP-2250 and Gemcitabine Prove to Be Highly Effective without the Development of Secondary Resistances In Vitro and In Vivo
por: Buchholz, Marie, et al.
Publicado: (2022) -
The effect of GP-2250 on cultured virus-negative Merkel cell carcinoma cells: preliminary results
por: Gambichler, Thilo, et al.
Publicado: (2023) -
In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes
por: Gambichler, Thilo, et al.
Publicado: (2023) -
Innovative substance 2250 as a highly promising anti-neoplastic agent in malignant pancreatic carcinoma - in vitro and in vivo
por: Buchholz, M., et al.
Publicado: (2017)